Open Nav

Locus Biosciences, Inc.

  • Paul Garofolo, Locus Biosciences, Inc.

Generate awareness of Locus and its CRISPR-engineered bacteriophage platform

  • Date:Wednesday, October 17
  • Time:10:30 AM - 10:45 AM
  • Room:Elizabethan D
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:Locus is developing powerful CRISPR-engineered bacteriophage (“crPhage”) products that kill target bacteria by irreversibly destroying their DNA while leaving the many species of good bacteria in the body unharmed. Our platform combines the antibacterial power of CRISPR-Cas3 with the efficient, safe delivery of bacteriophage. By bringing these technologies together, Locus is creating products that kill bacterial pathogens effectively with safety profiles that far exceed those of traditional antibiotics. crPhage therapies can address any bacterial pathogen at any site of infection, including those responsible for deadly acute infections and microbiome-associated diseases.
  • Company
  • Company HQ City:Research Triangle Park
  • Company HQ Country:United States
  • Company HQ State:North Carolina       
  • CEO/Top Company Official:Paul Garofolo
  • Year Founded:2015
  • Main Therapeutic Focus:Multiple Therapeutics
  • Lead Product in Development :LBx-UT01, a CRISPR-engineered phage cocktail targeting E. coli
  • Development Phase of Primary Product:Pre-Clinical
  • Number Of Unlicensed Products (For Which You Are Seeking Partners) :6
  • Additional Information/Comments:Product Pipeline: Locus is developing products to address significant unmet medical needs. Its lead program targeting Escherichia coli will enter clinical development in the first half of 2019 with a Phase 1b clinical trial in patients colonized with E. coli in their urinary tracts. This study will prove the viability of the crPhage mechanism in human subjects and give Locus critical data on pharmacokinetics, pharmacodynamics, and safety of these products. Locus has additional crPhage development programs targeting Clostridium difficile, Pseudomonas aeruginosa, Staphylococcus aureus, and other ESKAPE pathogens along with undisclosed bacterial targets that are relevant for inflammatory bowel disease (IBD) and other disorders caused by dysbiosis of the microbiome.
  • Previous and Current Investors:ARTIS Ventures, Tencent Holdings, Matrix Capital Management, Viking Global Investors
  • Size of Last Investment Round:$19M
  • Total Amount Raised to Date, In All Rounds:$25M
Paul Garofolo
Locus Biosciences, Inc.